A link between TIF-IA degradation and NF-κB signaling was observed in multiple colon cancer cells lines, in cell lines derived from human pre-malignant intestinal lesions and in four out of seven human tumors treated ex vivo with low doses of the agent, suggesting pharmacological relevance [4]. The gene discussed is NFKB1; the disease is malignant colon neoplasm.